Bradley Popovich, MSc, PhD, FACMG

President and Chief Executive Officer

Dr. Popovich brings a wealth of diagnostic and commercial expertise to Sirius. Preceding his role as CEO, Dr. Popovich was the Chief Operating Officer at Sirius Genomics. Prior to joining Sirius, Dr. Popovich was Vice President of Operations at Xenon Pharmaceuticals. Prior to that, Dr. Popovich was a tenured professor at Oregon Health Sciences University (OHSU) focusing on the characterization of the fragile X syndrome. Concurrently, he was also the Director for both the Clinical Genetic Laboratories and the DNA Diagnostic Laboratory in the University Hospital at OHSU where he was responsible for the development of molecular assays for a wide variety of genetic diseases. Dr. Popovich has been on the boards of Tm Bioscience and the American College of Medical Genetics, and he currently sits on the boards of the American College of Medical Genetics Foundation, DNA Direct, and Genome British Columbia. Dr. Popovich received his PhD from McGill University, and did his postdoctoral studies under Nobel Laureate, Dr. Oliver Smithies. He received his Postdoctoral Research Fellowship and Clinical Training at the University of Wisconsin and the University of North Carolina Schools of Medicine.

Keith Walley MD, FRCPC

Chief Scientific Officer & Co-founder

In addition to providing Sirius Genomics with his expertise on sepsis, Dr. Walley is currently a Professor at UBC and Associate Director of the James Hogg iCAPTURE Research Centre at St. Paul's Hospital (SPH). Over the past 15+ years at SPH, Dr. Walley has established a productive research program and has maintained continuous competitive research funding. Dr. Walley has co-edited a text with Dr. Russell on Acute Respiratory Distress Syndrome and has authored over 200 scientific publications. Additionally, Dr. Walley is Associate Editor of Principles of Critical Care and a Basic Science Editor for Critical Care Forum. In 2003, Dr. Walley was awarded one of only three Michael Smith Foundation for Health Research Distinguished Scientist Awards. Dr. Walley obtained his MD and specialty internal medicine, respiratory and critical care medicine and research training at the University of Manitoba, McGill University and the University of Chicago respectively.

Celia Courchene LLB

Vice President, Corporate Affairs

Ms. Courchene brings 20 years of experience in business development and business law to Sirius. Previously, Ms. Courchene was Vice President, Business Development at Xenon Pharmaceuticals and Vice President, Business Development & Legal Affairs at QLT. Preceding QLT, Ms. Courchene was with NeXstar Pharmaceuticals in Colorado. Ms. Courchene has negotiated business deals with a variety of local, national and international partners in both her business and legal careers. Ms. Courchene currently sits on the boards of Partnership British Columbia and The Vancouver Oral Centre for Deaf Children. She holds a bachelor of arts with honours in economics from the University of Western Ontario and a bachelor of law from the University of Victoria.

Jennifer Kaufman-Shaw PhD, LLB

Vice President, Intellectual Property

With significant prior experience in intellectual property in a biotech setting, Dr. Kaufman-Shaw brings over 15 years of scientific legal expertise to Sirius. Previously, Dr. Kaufman-Shaw was Vice President, Patent Counsel at QLT Inc. where for the last ten years she managed intellectual property matters at the company. Prior to becoming in-house counsel, Dr. Kaufman-Shaw was a practicing lawyer in the Technology Group of an established law firm. Dr. Kaufman-Shaw obtained both her PhD in biochemistry and her LLB from the University of Alberta.

Chris Wagner BSc

Vice President, Business Development

Chris Wagner joins Sirius Genomics with 15 years of collective experience in marketing, sales and business development. Previously, Mr. Wagner was with Aspreva Pharmaceuticals as the Vice President of Marketing, Vice President of Business Development and Vice President of Alliance Management. During his four year tenure there, Mr. Wagner initially directed and oversaw all aspects of Aspreva's marketing policies, objectives and initiatives for all markets worldwide. He then became responsible for managing the business development opportunities for the company. Prior to Aspreva, Mr. Wagner was with Eli Lilly as an international service employee working in Europe, North American and Asia with positions based in Toronto, Indianapolis and Boston. He has worked on the marketing plans for fifteen product launches including biologics and small molecules with annual sales ranging from tens of millions to over four billion dollars per year. Mr. Wagner holds a BSc in Organic Chemistry from the University of British Columbia.

James A. Russell MD, FRCPC

Co-founder

As a world leader in sepsis, Dr. Russell provides Sirius Genomics with crucial, relevant knowledge regarding critical care. Dr. Russell is currently a Professor of Medicine at the University of British Columbia and is Associate Director of the Intensive Care Unit at St. Paul's Hospital (SPH). Since joining SPH in 1982, Dr. Russell has established an internationally-recognized translational and clinical research program in critical care. He has authored over 320 publications, co-edited a text on Acute Respiratory Distress Syndrome, and has been on the editorial board of several journals. Additionally, he has worked closely with the pharmaceutical industry as an investigator on clinical trials (Phase II and III), investigator-initiated research and in a senior capacity on Scientific Advisory, Data and Safety Monitoring and Steering Committees. In 2003, he was the recipient for the University of British Columbia Martin F. Hoffman Award for Excellence in Research. Dr. Russell obtained his MD and FRCPC in internal medicine at the University of Toronto and did his Critical Care Medicine Fellowship (clinical and research) at the University of California, San Francisco.

Anthony Gordon MBBS, MD, FRCA

Dr Anthony Gordon obtained his medical degree from St Bartholomew's Hospital, London in 1993. He then trained in anesthesia and intensive care medicine in the North West Thames region, with an extra year spent at the Royal North Shore Hospital in Sydney, Australia. During his clinical post-graduate training, he became interested in genetic polymorphisms of the innate immune system in sepsis and coordinated a United Kingdom multi-centre study examining these effects. Dr Gordon was awarded the United Kingdom Intensive Care Society visiting fellowship and came to Vancouver in 2005 to work in the James Hogg iCAPTURE research centre with Drs. Russell and Walley. He has subsequently been a recipient of Canadian Lung Association and CIHR/HSFC IMPACT fellowships. Dr Gordon has scientific publications in a number of aspects of critical care medicine and has been a member of the UK Intensive Care Society Council and Research Committee.